Nykode Therapeutics – invitation to Q3 2024 financial results presentation

20 Nov 2024 18:00 CET

Oslo, Norway, November 20, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced it will release its third
quarter 2024 financial results before the opening of financial markets on
Wednesday, November 27, 2024.

The company will host a subsequent webcast presentation to review the financial
and operating results. A question-and-answer session will follow.

Third Quarter 2024 Webcast:

Date: Wednesday, November 27, 2024
Time: 8 a.m. CET / 2 a.m. ET
Webcast: https://event.webcasts.com/starthere.jsp?ei=1694735&tp_key=b3383a33dd


The financial report, as well as a live and archived webcast of the
presentation, can be accessed in the Investors section of the company’s website:
https://nykode.com/investors/financial-reports-and-presentations


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology
specifically targets antigens to antigen presenting cells (APC), employed with
their cancer vaccines to induce a broad, strong and long-lasting antigen
specific immune response, which correlates with clinical responses in cancer
patients.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies, which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer.
VB10.16 is being expanded into multiple trials for treatment of head and neck
cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen
vaccine, is being investigated in a trial with more than 10 different
indications.

The Company’s partnerships include a multi-target collaboration with Regeneron
in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse
vaccine platform for the potential use in autoimmune disorders, organ transplant
rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Contact:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.

More information:
Access the news on Oslo Bors NewsWeb site

632770_241120_Nykode Therapeutics_Q3 2024 Invitation to webcast_FINAL.pdf